Measuring the end-of-life premium in cancer using individual ex ante willingness to pay

S. Olofsson (), Ulf-G. Gerdtham, Lars Hultkrantz and U. Persson
Additional contact information
S. Olofsson: The Swedish Institute for Health Economics (IHE)
U. Persson: The Swedish Institute for Health Economics (IHE)

The European Journal of Health Economics, 2018, vol. 19, issue 6, No 5, 807-820

Abstract: Abstract For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some HTA agencies accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short expected remaining lifetime, a so-called end-of-life (EoL) premium. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 individuals in the Swedish general population 20–80 years old using a web-based questionnaire. Preferences were elicited using subjective risk estimation and the contingent valuation (CV) method. A split-sample design was applied to test for order bias. The mean value of a QALY was MSEK4.8 (€528,000), and there was an EoL premium of 4–10% at 6 months of expected remaining lifetime. Using subjective risk resulted in more robust and valid estimates of the value of a QALY. Order of scenarios did not have a significant impact on the WTP and the result showed scale sensitivity. Our result provides some support for the use of an EoL premium based on individual preferences when expected remaining lifetime is short and below 24 months. Furthermore, we find support for a value of a QALY that is above the current threshold of several HTA agencies.

Keywords: Willingness to pay; End of life; Value of a QALY; Cancer; Individual preferences; Contingent valuation (search for similar items in EconPapers)
JEL-codes: D61 D8 I18 J17 (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s10198-017-0922-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
Working Paper: Measuring the End of Life Premium in Cancer using Individual ex ante Willingness to Pay (2016)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:19:y:2018:i:6:d:10.1007_s10198-017-0922-6

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-017-0922-6

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().